Tracing the temporal stability of autism spectrum diagnosis and severity as measured by the Autism Diagnostic Observation Schedule: A systematic review and meta-analysis

łucja Bieleninik1*, Maj-Britt Posserud2,3*, Monika Geretsegger1‡, Grace Thompson4‡, Cochavit Elefant5‡, Christian Gold1***

1 GAMUT—The Grieg Academy Music Therapy Research Centre, Uni Research Health, Bergen, Norway, 2 Department of Child and Adolescent Psychiatry, Division of Psychiatry, Haukeland University Hospital, Bergen, Norway, 3 Department of Clinical Medicine, Faculty of Medicine and Dentistry, University of Bergen, Bergen, Norway, 4 Melbourne Conservatorium of Music, the University of Melbourne, Melbourne, Australia, 5 School for Creative Arts Therapies, University of Haifa, Haifa, Israel

* These authors contributed equally to this work.
‡ These authors also contributed equally to this work.

Abstract

Background
Exploring ways to improve the trajectory and symptoms of autism spectrum disorder is prevalent in research, but less is known about the natural prognosis of autism spectrum disorder and course of symptoms. The objective of this study was to examine the temporal stability of autism spectrum disorder and autism diagnosis, and the longitudinal trajectories of autism core symptom severity. We furthermore sought to identify possible predictors for change.

Methods
We searched PubMed, PsycInfo, EMBASE, Web of Science, Cochrane Library up to October 2015 for prospective cohort studies addressing the autism spectrum disorder/autism diagnostic stability, and prospective studies of intervention effects. We included people of all ages with autism spectrum disorder/autism or at risk of having autism spectrum disorder, who were diagnosed and followed up for at least 12 months using the Autism Diagnostic Observation Schedule (ADOS). Both continuous ADOS scores and dichotomous diagnostic categories were pooled in random-effects meta-analysis and meta-regression.

Results
Of 1443 abstracts screened, 44 were eligible of which 40 studies contained appropriate data for meta-analysis. A total of 5771 participants from 7 months of age to 16.5 years were included. Our analyses showed no change in ADOS scores across time as measured by Calibrated Severity Scores (mean difference [MD] = 0.05, 95% CI -0.26 to 0.36). We
observed a minor but statistically significant change in ADOS total raw scores (MD = -1.51, 95% CI -2.70 to -0.32). There was no improvement in restricted and repetitive behaviours (standardised MD [SMD] = -0.04, 95% CI -0.19 to 0.11), but a minor improvement in social affect over time (SMD = -0.31, 95% CI -0.50 to -0.12). No changes were observed for meeting the autism spectrum disorder criteria over time (risk difference [RD] = -0.01, 95% CI -0.03 to 0.01), but a significant change for meeting autism criteria over time (RD = -0.18, 95% CI -0.29 to -0.07). On average, there was a high heterogeneity between studies ($I^2$ range: 65.3% to 93.1%).

**Discussion**

While 18% of participants shifted from autism to autism spectrum disorder diagnosis, the overall autism spectrum disorder prevalence was unchanged.

Overall autism core symptoms were remarkably stable over time across childhood indicating that intervention studies should focus on other areas, such as quality of life and adaptive functioning. However, due to high heterogeneity between studies and a number of limitations in the studies, the results need to be interpreted with caution.

**Introduction**

Autism spectrum disorder is a neurodevelopmental disorder defined by persistent social and communication deficits and symptoms with associated restricted and repetitive behaviours and interests. Autism spectrum disorder is estimated to affect more than 1% of people worldwide, and to carry enormous cost for society and for the individual in loss of productive years and cost of educational support [1,2]. Longitudinal studies indicate that only 1 out of 5 individuals with autism spectrum disorder seem to obtain a good adult outcome as indicated by the quality of independent living, friendships and participation in employment [3]. Early intervention is believed to ameliorate this dire outlook, but the evidence for the long-term advantage of total population screening and intervention is still limited [4]. The lack of knowledge on the natural progression of autism spectrum disorder is one of the many challenges in research. Results of previous systematic reviews have suggested that autism is a stable diagnosis even before three years of age, although some children with cognitive impairments may initially be misclassified [5]. However, tracking autism spectrum disorder symptoms is hampered by the lack of valid and reliable measures of symptoms across the life-span and developmental level. Few measures currently exist to track the temporal stability of autism spectrum disorder and severity of the core symptoms over time, as several commonly used instruments (e.g. the Autism Behaviour Checklist, the Childhood Autism Rating Scale, the Gilliam Autism Rating Scale) are not independent of phenotypic characteristics such as age, IQ, and language level [6]. One exception is the Autism Diagnostic Observation Schedule (ADOS) [7], which has different modules tailored to the language level and age of the individual to ensure consistency of autism severity scores across cognitive levels and different age groups from infants to adults. Together with the Autism Diagnostic Interview-Revised [8], it is the current gold standard of autism spectrum disorder diagnosis worldwide [9]. Based on a semi-structured, clinician-administered assessment of the child’s behaviour, the scoring algorithm broadly classifies individuals into non-autism spectrum disorder, autism spectrum disorder, and autism.

Evaluating treatment effects on a neurodevelopmental disorder in children is intrinsically challenging. As all children develop and mature, it is difficult to reliably ascribe the change to
the intervention per se. The ADOS-based Calibrated Severity Scores (CSS) aims to minimize the impact of other factors such as age, language and cognitive ability on the autism severity score. The ADOS CSS has been suggested as the most appropriate measure of outcome for treatment and follow-up studies looking to capture change in symptom severity independent of developmental factors [6]; however ADOS raw totals have been used for many years and are still commonly used. However, little is known about the overall “natural” development of ADOS scores in individuals with autism spectrum disorder, and the magnitude of change that could be expected. To date, there has been no meta-analysis focusing on prospective cohort studies addressing the diagnostic stability over time of autism spectrum disorder/autism as measured by the ADOS. The motivation to undertake this study was thus to examine the temporal stability of autism spectrum disorder/autism diagnostic classification over time as measured by the ADOS and plot longitudinal trajectories of core autism symptom severity using the ADOS. The third aim was to identify possible predictors of change in autism spectrum disorder/autism as classified by the ADOS.

Methods

Search strategy

We undertook a comprehensive search following guidelines outlined in the PRISMA Statement (www.prisma-statement.org) (S1 and S2 Checklists). Methods of the analysis and inclusion criteria were specified in advance and documented in a protocol (S1 Protocol). PubMed, PsycInfo, Web of Science, EMBASE, DARE, and the Cochrane Library were searched up to September 10, 2014 for the term “Autism Diagnostic Observation Schedule” by one reviewer (ŁB). An update search was conducted on October 12, 2015. The search was not restricted to any language, reference type, or year of publication. Unpublished studies such as conference abstracts and dissertation abstracts were also included. Reference lists of the included review articles were checked to identify any additional studies.

Study selection

Titles and abstracts of all references identified were inspected independently by two reviewers (ŁB, MBP) to exclude obviously irrelevant reports. Any disagreement was solved through discussion, and consultation with a third reviewer (CG). The final selection of remaining references was based on full-text assessment by three reviewers independently (ŁB, MG, MBP), with at least two assessing every record. Final inclusion was based on the following inclusion criteria:

1. Participants: individuals of any age (including adults) diagnosed with any autism spectrum disorder as defined in DSM-5 [10], or similarly as based on earlier versions of the DSM or the International Classification of Diseases (ICD). This included childhood autism, atypical autism, Asperger syndrome, and pervasive developmental disorder not otherwise specified (PDD-NOS) and autism spectrum disorder, excluding Rett syndrome. We also included individuals at risk of having autism spectrum disorder (e.g. siblings with autism spectrum disorder or through screening instruments).

2. Baseline assessment: A version of the ADOS (ADOS/ADOS-G/ADOS-2/ADOS toddler version) was used as diagnostic measure.

3. Follow-up assessment: A version of the ADOS was used a second time at least 12 months later. If participants were evaluated using ADOS more than twice, we analysed the longest available time span.
4. Type of study: prospective cohort studies addressing the diagnostic stability over time of autism spectrum disorder/autism; or prospective studies of intervention effects (i.e., randomised, non-randomised controlled, or without a control group).

Duplicate publication detection was based on author names, location and setting, specific details of the interventions, numbers of participants and baseline data; and date and duration of the study. When uncertainties remained, we contacted authors.

Data collection and extraction process
Data were independently extracted by two authors (GT, CE). They confirmed accuracy using a shared, piloted data extraction sheet on participant characteristics at baseline (diagnosed vs. high risk, number, age at initial diagnosis using ADOS, gender), clinical subgroups, study design, interventions, age at follow up, attrition, and outcome category (ADOS total vs. CSS, ADOS subscales, autism spectrum disorder/autism cut-offs). Any disagreements were resolved by discussion with other reviewers (CG, MG, ŁB) and with study authors when required.

Quality of included studies
Study quality was rated as low when overall attrition was more than 20%. Randomised controlled trials (RCTs) were rated as “low quality” if there was no blinding. Studies failing to report the total number assessed at baseline and RCT studies failing to report blinding status were labelled as of “uncertain quality”.

Preparatory data analyses
When study results were split according to clinical characteristics, we prepared them as follows: we retained subgroups assigned prospectively (e.g. to intervention vs. control, or divisions between diagnostic groups) [11–16] because they might contain important information on heterogeneity. For studies that separated participants retrospectively (e.g., into improved or not improved [17] or retrospective diagnostic groups [18,19]), without pooled data available from the paper or the authors, we pooled these subsamples using means and pooled SDs.

Meta-analysis and meta-regression
Meta-analysis was performed for the following outcomes:

1. Total autism severity: either raw scores using any of the published algorithms, or CSS. We prioritized CSS over raw total scores if both were available for the complete sample.

2. Autism severity, subdomain social affect: social affect subtotal, or social+communication total, or (language and) communication domain & social (interaction) domain, or modified scores thereof.

3. Autism severity, subdomain restricted and repetitive behaviour: restricted and repetitive behaviour subtotal, or modified score thereof.

4. Meeting autism spectrum disorder criteria, based on ADOS cut-off value (i.e. ≥ 4 on the CSS, or ≥ 7 to ≥ 11 in the different modules of ADOS raw totals [6]; differing between earlier and later ADOS versions). (Note that this includes those who also meet the higher cut-off for autism. This is in line with diagnostic criteria, but semantically different from the use in ADOS CSS [6].)
5. Meeting autism criteria, based on ADOS cut-off value (i.e. ≥ 6 on the CSS, or ≥ 9 to ≥ 16 in the different modules of ADOS raw totals [6]; differing between earlier and later ADOS versions).

For continuous variables, we used primarily weighted mean differences (MDs). For ADOS raw scores (which have similar but not identical meaning due to various adaptations, versions, and modules used), we also examined whether using standardized mean differences (SMDs) affected results. This was not necessary for ADOS CSS, where the scores have the same meaning across ADOS modules. The ADOS subscales social affect and restricted and repetitive behaviour were analysed using SMD as they were reported in various forms. Dichotomous variables were evaluated using risk differences (RDs) because they are straightforward to interpret as percentage point change.

We calculated both fixed-effects and random-effects meta-analyses, but report only random effects because heterogeneity between studies was high ($I^2 \geq 50\%$) in all main analyses. As potential predictor variables, we analysed initial age, initial diagnosis (diagnosed vs. high-risk), duration of follow-up, and type of intervention (specific vs. carer training vs. standard care), using random-effects meta-analysis and meta-regression. All analyses were conducted using R version 3.3.1 (http://www.r-project.org) and R package meta.

Results

Results of the search

The combined literature search yielded 1443 titles. After excluding duplicates and clearly irrelevant papers, we examined full-text articles of 105 potentially relevant studies. The update search yielded 29 new potentially relevant articles of which 9 were included. Finally, 44 articles met inclusion criteria. Four publications referring to already included studies [11,13,18] were merged with those, leaving forty studies appropriate for meta-analysis (Fig 1).

Characteristics of the included studies

We included 40 studies with a total of 5771 participants (range: 12 to 1241) (Table 1). Age at baseline ranged from seven months [20] to 16.5 years [21], i.e. no studies of adults existed for inclusion. Gender distribution was not always reported, but ranged from 39% [22] to 100% males [23,24]. Ten studies included high-risk children, twenty-nine included children diagnosed with autism spectrum disorder, and one study [15] included separate samples of both types. Some studies also included comparison groups of low-risk children, which were outside the scope of this review. Most studies (n = 35) were prospective cohort studies, whereas five were RCTs. Some study samples were divided either prospectively or retrospectively into clinical subgroups (Table 1). Follow-up duration ranged from 12 months to 17 years [11], with a median of 18.5 months (mean 30.45; SD 34.22).

Quality of studies

Many studies did not specify attrition rates and were defined as of uncertain quality and risk of bias. Four of the five RCTs and 10 of the 35 prospective cohort studies were rated as good quality (Table 2).

Stability of autism spectrum disorder over time

Overall severity of autism symptoms. We performed two separate meta-analyses of overall severity of autism symptoms for ADOS total scores and CSS. There was high heterogeneity
between studies for severity of autism symptoms both as expressed in ADOS total scores ($I^2 = 85.6\%$; Fig 2A) and in CSS ($I^2 = 75.5\%$; Fig 2B). Significant changes were observed for severity of autism symptoms in ADOS total scores over time ($\text{MD} = -1.51$, 95% CI -2.70 to -0.32). No
| Study                        | Participant characteristics at baseline | Design type | Intervention type | Clinical subgroups | Follow-up | Outcomes reported | Data used |
|-----------------------------|-----------------------------------------|-------------|-------------------|--------------------|-----------|-------------------|-----------|
| Aleksandravicius et al. 2003 | 41 (23–58)                             | CS          | Standard care     | —                  | —         | None              | ASD P     |
| Aldred et al. 2004          | 48 (24–71)                              | RCT         | Carer training, standard care | —                  | 12        | None              | Total SA, RRB AD P |
| Anderson et al. 2014        | 30 (23–NA)                              | CS          | Standard care     | IQ < 70, IQ ≥ 70    | 204       | None              | SA, RRB ASD P |
| Ben Itzhak et al. 2001      | 25 (18–35)                              | CS          | Specific          | —                  | 12        | Total             | — AD P    |
| Biss et al. 2008            | 18 (16–20)                              | CS          | Standard care     | —                  | 18        | —                 | ASD P     |
| Chawarska et al. 2009       | 22 (13–27)                              | NA          | CS                | Specific, standard care | True, false positive screens | 21       | 13/41 CSS         | AD P     |
| Chawarska et al. 2014       | 18 (NA)                                 | CS          | Specific          | —                  | 18        | CSS               | — P       |
| Dawson et al. 2010          | 24 (18–30)                              | RCT         | Specific, standard care | —                  | 24        | 3/48 CSS          | AD P     |
| Denu et al. 2012            | 30 (25–NA)                              | CS          | Specific, standard care | —                  | 55        | CSS               | SA, RRB ASD P |
| Di Renzo et al. 2015        | 78 (30–198)                             | CS          | Specific          | —                  | 48        | Total             | ASD, AD P |
| Freitag et al. 2012         | 70 (48–92)                              | CS          | Specific          | —                  | 12        | CSS               | — P       |
| Gammer et al. 2015          | 24 (NA)                                 | CS          | Standard care     | —                  | 12        | CSS               | — P       |
| Gotham et al. 2012          | 34 (34–99)                              | CS          | Standard care     | —                  | 55        | CSS               | SA, RRB ASD AD P |
| Green et al. 2010           | 45 (24–66)                              | RCT         | Carer training, standard care | —                  | 13        | —                 | SA, RRB ASD AD P |
| Guthrie et al. 2013         | 19 (15–24)                              | CS          | Standard care     | —                  | 17        | —                 | SA, RRB ASD P |
| Gutstein et al. 2007        | 61 (21–94)                              | CS          | Carer training    | —                  | 36        | —                 | ASD, AD P |
| Hobson et al. 2016          | 73 (NA)                                 | CS          | Carer training    | —                  | 26        | CSS               | — P       |
| Howlin et al. 2007          | 82 (19–22–72)                           | CS          | Standard care     | —                  | 16        | Total             | SA, ASD, AD P |
| Kleinman et al. 2008        | 27 (16–35)                              | CS          | Standard care     | AD, PDD-NOS        | 19        | Total             | — P       |
| Klin et al. 2015            | 22 (NA)                                 | CS          | Specific          | —                  | 16        | Total             | — P       |
| Landa et al. 2013           | 15 (13–16)                              | CS          | Standard care     | Early, later diag. | 22        | 1/54              | SA, RRB — P |
| Lema et al. 2014            | 69 (18–60)                              | CS          | Specific, standard care | —                  | 12        | Total             | SA — P     |
| Lord et al. 2006            | 24 (12–18)                              | NA          | Standard care     | AD, PDD-NOS, TD    | 84        | Total (+CSS for subsample) | SA, RRB AD U |
| Lord et al. 2012            | 17 (12–18)                              | CS          | Standard care     | ASD (severe persistent, worsening, improving), TD | 18        | Total (+CSS for subsample) | SA, RRB AD U |
| Louerse et al. 2015         | 110 (72–144)                            | CS          | Standard care     | Stable, worsening, improving | 83        | CSS               | SA, RRB ASD U |
| Macari et al. 2012          | 12 (NA)                                 | CS          | Standard care     | ASD, AD, TD        | 12        | Total             | — P       |
| Messinger et al. 2015       | 24 (24–NA)                              | CS          | Standard care     | ASD, non-ASD       | 12        | —                 | SA, RRB — U |

(Continued)
Table 1. (Continued)

| Study                      | Participant characteristics at baseline¹ | Design type² | Intervention type³ | Follow-up | Outcomes reported | ADOS overall (total or CSS)⁴ | ADOS subscales ⁵ | Data used⁶ |
|---------------------------|------------------------------------------|--------------|-------------------|-----------|-------------------|-------------------------------|----------------|-----------|
| Diag.                     | N 53                                     | Age at baseline in months; mean (range) 31 (18–35) | Male (%) 92 | CS Standard care — | — | 24 | 26/53 | ASD | P |
| Ozonoff 2014 [20]         | HR                                      | 294          | 7 (NA)            | NA        | CS Standard care — | ASD, ATD, TD | 18 | — | SA | U |
| Ray-Subramanian 2012 [42] | Diag.                                   | 115          | 31 (24–36)        | 84        | CS Standard care — | — | 13 | — | RRB | ASD | P |
| Richler 2010 [43]         | Diag.                                   | 214          | 24 (24–24)        | 80        | CS Standard care — | — | 84 | — | ASD, AD | P |
| Shumway 2012 [44]         | Diag.                                   | 89           | 49 (24–144)       | 87        | CS Standard care — | — | 17 | Total | — | — | U |
| Solomon 2014 [45]         | Diag.                                   | 128          | 50 (32–71)        | 82        | RCT Carer training, standard care — | — | 12 | — | ASD | P |
| Szatmari 2015 [46]        | Diag.                                   | 406          | 40 (NA)           | 84        | CS Standard care — | — | 35 | CSS | — | — | P |
| Thurm 2015 [47]           | Diag.                                   | 70           | 41 (12–60)        | 81        | CS Standard care — | Minimally verbal, phrase speech | 27 | CSS | SA, RRB | — | P |
| Turner 2007 [48]          | Diag.                                   | 48           | 29 (24–35)        | 81        | CS Standard care — | — | 24 | — | ASD, AD | P |
| van Daalen 2009 [16]      | HR                                      | 131          | 26 (NA)           | 85        | CS Standard care AD, PDD-NOS, non-ASD | 19 | — | SA, RRB | ASD, AD | P |
| Venker 2014 [49]          | Diag.                                   | 127          | 31 (23–39)        | 87        | CS Standard care — | — | 36 | CSS | — | — | P |
| Vivanti 2014 [50]         | Diag.                                   | 57           | 41 (18–60)        | 88        | CS Specific, standard care — | — | 12 | CSS | SA, RRB | ASD, AD | P |
| Zachor 2007 [51]          | Diag.                                   | 39           | 28 (22–34)        | 95        | RCT Specific, standard care — | — | 12 | — | SA, RRB | ASD, AD | P |

NA—not available.

1 Listing only those relevant to this review.
2 CS—prospective cohort study; RCT—randomised controlled trial.
3 Our categorisation; see main text for descriptions.
4 AD—autistic disorder; ASD—autism spectrum disorder; ATD—atypical development; IQ—intelligence quotient; PDD-NOS—pervasive developmental disorder not otherwise specified; TD—typical development
5 P—published data only; U—unpublished and published data.
6 Diag.—diagnosed; HR—high risk.
7 Subgroups from retrospective classifications were pooled in the meta-analysis to avoid inflated heterogeneity estimates.
8 CSS—calibrated severity score.
9 SA—social affect (incl. subscales communication and reciprocal social interaction in earlier ADOS versions); RRB—repetitive and restricted behaviour.

https://doi.org/10.1371/journal.pone.0183160.t001
significant changes were observed for severity of autism symptoms in CSS over time (MD = 0.05, 95% CI -0.26 to 0.36).

Severity of autism symptom subdomains. The ADOS social affect subdomain showed high heterogeneity between studies ($I^2 = 88.1\%$) with a significant improvement of medium
effect size over time (SMD = -0.31, 95% CI -0.50 to -0.12; Fig 3A), while the ADOS restricted and repetitive behaviour subdomain showed high heterogeneity between studies (I² = 79.8%) with no significant improvement over time (SMD = -0.04, 95% CI -0.19 to 0.11; Fig 3B).

**Proportion meeting diagnostic criteria.** Heterogeneity between studies was high (I² ≥ 50%) for both autism (I² = 93.1%; Fig 4B) and autism spectrum disorder (I² = 65.3%; Fig 4A). Significant changes were observed for meeting autism diagnostic criteria over time (RD = -0.18, 95% CI -0.29 to -0.07; Fig 4B). This risk difference of -0.18 means that 18% of children did not meet the autism criteria at follow-up; numbers meeting autism spectrum disorder criteria at baseline and follow-up, along with the observed totals in each study, are shown in Fig 4B. No changes were observed for meeting autism spectrum disorder criteria over time (RD = -0.01, 95% CI -0.03 to 0.01; Fig 4A).
Fig 3. Severity of autism symptom subdomains. Panel a–social affect. Panel b–restricted and repetitive behaviour. MD–mean difference (difference in points on the scale from baseline to follow-up).

https://doi.org/10.1371/journal.pone.0183160.g003
A

| Study                      | Follow-up Events Total | Baseline Events Total | Risk Difference | RD  | 95%-CI W(random) |
|----------------------------|------------------------|-----------------------|-----------------|-----|------------------|
| Turner 2007                | 22 48 40 48            |                       | -0.38 [-0.55; -0.20] | 1.2% |
| Anderson 2014 (ASD IQ>70)  | 24 32 32 32            |                       | -0.25 [-0.40; -0.10] | 1.5% |
| Akshoomoff 2004            | 42 52 52 52            |                       | -0.19 [-0.30; -0.08] | 2.6% |
| Green 2010 (Control)       | 67 72 72 72            |                       | -0.07 [-0.13; -0.01] | 5.4% |
| Green 2010 (Intervention)  | 70 74 74 74            |                       | -0.05 [-0.11; 0.00]  | 6.0% |
| Gotham 2012                | 332 339 339 339        |                       | -0.02 [-0.04; 0.00]  | 10.8%|
| Anderson 2014 (ASD IQ<70)  | 53 53 53 53            |                       | 0.00 [-0.04; 0.04]   | 8.4% |
| Dereu 2012 (ASD)           | 15 41 15 41            |                       | 0.00 [-0.21; 0.21]   | 0.9% |
| Howlin 2007                | 82 82 83 83            |                       | 0.00 [-0.02; 0.02]   | 10.0%|
| Mosconi 2009 (AD)          | 27 27 53 53            |                       | 0.00 [-0.06; 0.06]   | 6.2% |
| Ray-Subramanian 2012       | 115 115 115 115        |                       | 0.00 [-0.02; 0.02]   | 10.7%|
| Solomon 2014 (Intervention)| 64 64 64 64            |                       | 0.00 [-0.03; 0.03]   | 9.2% |
| Solomon 2014 (Control)     | 64 64 64 64            |                       | 0.00 [-0.03; 0.03]   | 9.2% |
| Di Renzo 2015              | 30 90 29 90            |                       | 0.01 [-0.13; 0.15]   | 1.8% |
| Brian 2008                 | 35 155 32 155          |                       | 0.02 [-0.07; 0.11]   | 3.4% |
| Louwverse 2015             | 41 72 39 72            |                       | 0.03 [-0.13; 0.19]   | 1.3% |
| Richler 2010               | 135 172 161 214        |                       | 0.03 [-0.05; 0.12]   | 3.8% |
| Guthrie 2013               | 59 82 56 82            |                       | 0.04 [-0.10; 0.18]   | 1.7% |
| van Daalen 2009            | 22 131 13 131          |                       | 0.07 [-0.01; 0.15]   | 3.9% |
| Zachor 2007 (Control)      | 4 19 1 19              |                       | 0.16 [-0.05; 0.37]   | 0.9% |
| Zachor 2007 (intervention) | 5 20 1 20              |                       | 0.20 [-0.01; 0.41]   | 0.8% |
| Gutstein 2007              | 6 16 2 12              |                       | 0.21 [-0.11; 0.53]   | 0.4% |

Random effects model 1820 1885 0.01 [-0.03; 0.01] 100%

Heterogeneity: I-squared=65.3%, tau-squared=0.0009, p=0.0001

B

| Study                      | Follow-up Events Total | Baseline Events Total | Risk Difference | RD  | 95%-CI W(random) |
|----------------------------|------------------------|-----------------------|-----------------|-----|------------------|
| Gutstein 2007              | 0 16 10 12             |                       | -0.83 [-1.06; -0.60] | 5.3% |
| Zachor 2007 (Intervention) | 11 20 19 20            |                       | -0.40 [-0.64; -0.16] | 5.2% |
| Green 2010 (Intervention)  | 48 74 74 74            |                       | -0.35 [-0.46; -0.24] | 6.5% |
| Turner 2007                | 32 48 48 48            |                       | -0.33 [-0.47; -0.20] | 6.3% |
| Gotham 2012                | 230 339 339 339        |                       | -0.32 [-0.47; -0.27] | 6.9% |
| Green 2010 (Control)       | 50 72 72 72            |                       | -0.31 [-0.41; -0.20] | 6.5% |
| Di Renzo 2015              | 34 90 61 90            |                       | -0.30 [-0.44; -0.16] | 6.2% |
| Ben Itzchak 2009 (AD)      | 53 68 68 68            |                       | -0.22 [-0.32; -0.12] | 6.6% |
| Zachor 2007 (Control)      | 15 19 18 19            |                       | -0.16 [-0.37; 0.05]  | 5.5% |
| van Daalen 2009            | 26 131 40 131          |                       | -0.11 [-0.21; 0.00]  | 6.6% |
| Chawarska 2009 (AD)        | 36 89 43 89            |                       | -0.08 [-0.22; 0.07]  | 6.2% |
| Dawson 2010                | 36 45 39 48            |                       | -0.01 [-0.17; 0.15]  | 6.0% |
| Howlin 2007                | 75 82 75 83            |                       | 0.01 [-0.08; 0.10]   | 6.7% |
| Richler 2010               | 100 172 102 214        |                       | 0.10 [0.01; 0.20]    | 6.6% |
| Chawarska 2009 (PDD-NOS)   | 28 89 18 89            |                       | 0.11 [-0.02; 0.24]   | 6.4% |
| Lord 2006                  | 100 172 84 192         |                       | 0.14 [0.04; 0.25]    | 6.6% |

Random effects model 1526 1588 -0.18 [-0.29; -0.07] 100%

Heterogeneity: I-squared=93.1%, tau-squared=0.0428, p=0.0001

Fig 4. Proportion meeting diagnostic criteria. Panel a—autism spectrum disorder. Panel b—autism. RD—risk difference (difference in percentage of participants meeting the cut-off from baseline to follow-up).

https://doi.org/10.1371/journal.pone.0183160.g004
Subgroup analyses

Subgroup analyses were conducted to examine differences attributable to type and age of participants, type of intervention, and duration of follow-up. An overview of the results is given in Table 3.

**Type of participants.** Participant type was a significant predictor of ADOS CSS (p = 0.005) and autism spectrum disorder (ADOS instrument classification) cut-off (p = 0.04; first part of Table 3). Significant deterioration by about half a point on the ADOS CSS was observed for the subgroup at high risk (MD 0.56, 95% CI 0.15 to 0.97, residual heterogeneity I² = 23%), whereas those with a diagnosis at baseline did not change (MD -0.15, 95% CI -0.42 to 0.13; Table 3). For the proportion meeting the autism spectrum disorder (ADOS instrument classification) cut-off, marginal improvement was observed for those with a diagnosis at baseline (RD -0.02, 95% CI -0.04 to 0.00; i.e. a reduction by 2 percentage points; but with high residual heterogeneity of I² = 74%), compared to no significant change in the high risk subgroup (RD 0.04, 95% CI -0.01 to 0.10; i.e. a non-significant increase by 4 percentage points; Table 3). Forest plots of the meta-analyses where this predictor was significant are available in the supplemental material (S1 and S2 Figs).

**Participants’ age.** There were no statistically significant effects of participants’ age on ADOS total score, ADOS CSS, ADOS SA, ADOS RRB, ASD cut-offs, and autism cut-offs (second part of Table 3).

**Type of intervention.** The type of intervention predicted changes on ADOS total scores (p = 0.001), but not on any other measure (third part of Table 3). Significant improvements were observed in those who received a specific intervention (MD -3.57, 95% CI -4.63 to -2.52, I² = 41%; i.e. an improvement of about four points on the ADOS total scale) compared to no change in children who received standard care (MD -0.52, 95% CI -2.16 to 1.13) or carer training (MD -0.83, 95% CI -2.33 to 0.66; Table 3) on this scale.

**Duration of follow up.** Longer duration of follow-up was associated with greater improvements in the two ADOS subscales, but not on the other measures (last part of Table 3). For the ADOS social affect, improvement increased by 0.05 points per year (p = 0.025; regression coefficient -0.05, 95% CI -0.09 to -0.01), corresponding to half a point over ten years. ADOS restricted and repetitive behaviour scores improved by 0.03 points per year (p = 0.042; regression coefficient -0.03 per year, 95% CI -0.07 to 0.00; Table 3), or one-third of a point over ten years. The magnitude of change was small even after ten years or more, and there were only few samples with long follow-up duration (Fig 5).

**Discussion**

Although autism spectrum disorder/autism diagnosis and tracking autism symptoms over time has long been of interest [5,52,53], to our knowledge this is the first comprehensive meta-analysis examining the temporal stability of autism spectrum disorder (as defined by ADOS instrument classification) and severity of autism symptoms using the ADOS. We found no change in ADOS scores across time as measured by the most phenotypically stable autism core symptom measure; the CSS. There was a minor but statistically significant change in ADOS total scores (1.51 point reduction across up to 15 years) and a minor reduction in the subdomain of social affect symptoms (-0.31 points). There was an 18% reduction (risk difference -0.18, 95% CI -0.29 to -0.07; Fig 4B) of children meeting the autism criteria according to ADOS total scores, but no change in overall autism spectrum disorder prevalence, suggesting that some children move from autism to other autism spectrum disorder diagnoses. Although not salient in the overall analyses, sub-group analyses on ADOS total scores also showed that a net 2% fulfilling autism spectrum disorder cut-off diagnosis (ADOS instrument classification)
Table 3. Random effects meta-analyses and linear mixed-effects meta-regression models.

### Categorical predictor: Type of participants

| Outcome (statistic used) | P-value | Predictor level | Number of samples | Number of participants | Estimate (95% CI) | Residual heterogeneity ($I^2$) |
|--------------------------|---------|-----------------|-------------------|-----------------------|-------------------|-------------------------------|
| ADOS Total (MD)          | 0.340   | diagnosed       | 13                | 503                   | -1.88 (-2.92 to -0.85) | 74% |
|                          |         | high risk       | 3                 | 329                   | 0.02 (-3.75 to 3.79)  | 94% |
| ADOS Calibrated Severity Score (MD) | 0.005 ** | diagnosed       | 11                | 1156                  | -0.15 (-0.42 to 0.13)  | 48% |
|                          |         | high risk       | 3                 | 784                   | 0.56 (0.15 to 0.97)  | 23% |
| ADOS Social Affect Total (SMD) | 0.136    | diagnosed       | 21                | 1250                  | -0.23 (-0.50 to 0.04)  | 89% |
|                          |         | high risk       | 9                 | 1347                  | -0.53 (-0.83 to -0.24)  | 83% |
| ADOS Restr. and Rep. Beh. Total (SMD) | 0.560    | diagnosed       | 14                | 1208                  | 0.01 (-0.17 to 0.18)  | 73% |
|                          |         | high risk       | 9                 | 1347                  | -0.10 (-0.43 to 0.22)  | 86% |
| Autism spectrum cut-off (RD) | 0.040 *  | diagnosed       | 18                | 1476                  | -0.02 (-0.04 to 0.00)  | 74% |
|                          |         | high risk       | 4                 | 409                   | 0.04 (-0.01 to 0.10)  | 0%  |
| Autism cut-off (RD)      | 0.098   | diagnosed       | 14                | 1265                  | -0.21 (-0.32 to -0.10)  | 92% |
|                          |         | high risk       | 2                 | 323                   | 0.02 (-0.23 to 0.27)  | 91% |

### Continuous predictor: Age at baseline (years)

| Outcome (statistic used) | P-value | Number of samples | Number of participants | Regression coefficient (95% CI) | Residual heterogeneity ($I^2$) |
|--------------------------|---------|-------------------|-----------------------|---------------------------------|-------------------------------|
| ADOS Total (MD)          | 0.774   | 16                | 832                   | -0.08 (-0.64 to 0.48)           | 86% |
| ADOS Calibrated Severity Score (MD) | 0.922     | 14                | 1940                 | -0.01 (-0.17 to 0.16)          | 74% |
| ADOS Social Affect Total (SMD) | 0.204   | 30                | 2597                  | 0.07 (-0.04 to 0.17)           | 88% |
| ADOS Restr. and Rep. Beh. Total (SMD) | 0.773   | 23                | 2555                  | -0.01 (-0.11 to 0.08)          | 81% |
| Autism spectrum cut-off (RD) | 0.925   | 22                | 1885                  | 0.00 (-0.01 to 0.01)           | 67% |
| Autism cut-off (RD)      | 0.122   | 16                | 1588                  | -0.05 (-0.12 to 0.01)          | 93% |

### Categorical predictor: Type of intervention

| P-value | Predictor level | Number of samples | Number of participants | Estimate (95% CI) | Residual heterogeneity ($I^2$) |
|---------|-----------------|-------------------|-----------------------|-------------------|-------------------------------|
| ADOS Total (MD) | 0.001 **  | standard care     | 8                     | 500                | -0.52 (-2.16 to 1.13)       | 84% |
|          |                | carer training    | 4                     | 97                 | -0.83 (-2.33 to 0.66)       | 50% |
|          |                | specific          | 4                     | 235                | -3.57 (-4.63 to -2.52)      | 41% |
| ADOS Calibrated Severity Score (MD) | 0.067  | standard care     | 10                    | 1858               | 0.12 (-0.23 to 0.47)        | 81% |
|          |                | carer training    | 1                     | 18                 | -1.56 (-2.94 to -0.18)      | —    |
|          |                | specific          | 3                     | 64                 | 0.08 (-0.52 to 0.68)        | 0%   |
| ADOS Social Affect Total (SMD) | 0.416   | standard care     | 22                    | 2369               | -0.28 (-0.51 to -0.06)      | 90% |
|          |                | carer training    | 5                     | 174                | -0.23 (-0.65 to 0.19)       | 70% |
|          |                | specific          | 3                     | 54                 | -0.74 (-1.41 to -0.07)      | 59% |
| ADOS Restr. and Rep. Beh. Total (SMD) | 0.383 | standard care     | 20                    | 2444               | 0.00 (-0.16 to 0.15)        | 81% |
|          |                | carer training    | 1                     | 77                 | -0.19 (-0.50 to 0.13)       | —    |
|          |                | specific          | 2                     | 34                 | -0.58 (-1.67 to 0.52)       | 66% |
| Autism spectrum cut-off (RD) | 0.873   | standard care     | 17                    | 1562               | -0.02 (-0.04 to 0.01)       | 71% |
|          |                | carer training    | 4                     | 233                | -0.01 (-0.03 to 0.02)       | 39% |
|          |                | specific          | 1                     | 90                 | 0.01 (-0.13 to 0.15)        | —    |

(Continued)
Table 3. (Continued)

| Outcome (statistic used) | P-value | Number of samples | Number of participants | Regression coefficient (95% CI) | Residual heterogeneity ($I^2$) |
|--------------------------|---------|-------------------|------------------------|---------------------------------|-------------------------------|
| Autism cut-off (RD)      | 0.510   | standard care     | 9                      | -0.15 (-0.30 to 0.00)           | 94%                           |
| carer training           | 3       | 169               | 97%                    |
| specific                 | 4       | 336               | 87%                    |

**Continuous predictor: Duration of follow-up (years)**

| Outcome (statistic used) | Number of samples | Number of participants | Regression coefficient (95% CI) | Residual heterogeneity ($I^2$) |
|--------------------------|-------------------|------------------------|---------------------------------|-------------------------------|
| ADOS Total (MD)          | 0.341             | 16                     | 832                             | -0.36 (-1.09 to 0.38)         | 85%                           |
| ADOS Calibrated Severity Score (MD) | 0.879         | 14                     | 1940                            | -0.02 (-0.22 to 0.19)         | 73%                           |
| ADOS Social Affect Total (SMD) | 0.025 *       | 30                     | 2597                            | -0.05 (-0.09 to -0.01)        | 86%                           |
| ADOS Restr. and Rep. Beh. Total (SMD) | 0.042 *       | 23                     | 2555                            | -0.03 (-0.07 to 0.00)         | 79%                           |
| Autism spectrum cut-off (RD) | 0.449       | 22                     | 1885                            | 0.00 (-0.01 to 0.00)          | 67%                           |
| Autism cut-off (RD)      | 0.164             | 16                     | 1588                            | 0.04 (-0.02 to 0.09)          | 93%                           |

MD–mean difference; RD–risk difference; SMD–standardised mean difference.

* $p < .05$
** $p < .01$

https://doi.org/10.1371/journal.pone.0183160.t003

Fig 5. Results of meta-regression analyses. Shows magnitude of changes as a function of follow-up duration. Circles represent individual studies, with circle sizes representing sample sizes.

https://doi.org/10.1371/journal.pone.0183160.g005
at baseline lost their diagnosis (risk difference -0.02, 95% CI -0.04 to 0.00; Table 3, autism spectrum cut-off/participant type diagnosed). The only significant change of sub-group analyses for CSS was a deterioration of individuals at risk compared to already diagnosed children. This is also the most robust finding with low heterogeneity (23%).

The scientific community view ASD as a neurodevelopmental disorder, similar to other neurodevelopmental disorders such as intellectual disability and language disorders. The very name—pervasive developmental disorder—further highlights this view. When it comes to treatment research however, ASD is approached quite differently from intellectual disability; interventions are often evaluated using measures of core autism symptoms such as the ADOS. Intervention programs for intellectual disability on the other hand rarely aim for improvement of the intellectual disability but rather at improved outcome, functioning and well-being. Although the ADOS is probably not a sensitive measure of change and thus may underestimate possible change, our findings do support the view of ASD as a stable neurodevelopmental disorder at group level. Consequently, intervention studies should focus less on core autism symptoms in favour of areas more relevant to the affected individuals such as quality of life, general functioning and outcome.

The relative improvement of ADOS total scores versus no improvement in CSS may indicate that studies using ADOS total scores as an outcome measure may achieve artificial improvements due to changes between ADOS modules and general development rather than a true change of core autism symptoms [6]. The rationale for creating the CSS was to provide a more stable measure for longitudinal studies. This developmental bias will have a particular impact in studies of young children, where there are more frequent shifts in ADOS modules. Most included studies only reported either CSS or ADOS total scores, making direct comparisons across all studies impossible. Findings highlight a crucial role for ADOS CSS as a measure of severity of autism symptoms in being less sensitive to phenotypic and environmental changes than ADOS total scores. The high heterogeneity for ADOS total scores analyses (85.7%; Fig 2A) may indicate that the raw total scores are significantly influenced by individual phenotypical characteristics and demographics and may therefore be a problematic measure of autism symptom severity [6,54]. As intended, CSSs are more uniformly distributed within diagnostic categories (autism, PDD-NOS, non-autism spectrum, or typical development) and across assessment modules than are total scores [55].

Research on change in autism symptoms subdomains over time is still emerging. Our results indicate that individuals with autism symptoms may show some change in social affect (such as pointing/showing, gestures, eye contact, joint attention, social overtures, and others), but not in restricted and repetitive behaviours (such as unusual sensory interest in play, self-injurious behaviours, stereotyped behaviours). However, the change in social affect was small (-0.31 points) and may be an artefact of applying different modules across development, as CSSs were stable. The lack of change in both raw scores and CSS scores in the RRBI subdomain is likely due to the lesser impact of module change noted for the RRBI domain as already shown by Hus et al. [56]. Our results are in line with previous research by Hus et al. showing that restricted and repetitive behaviours are more persistent over time and less sensitive to children’s phenotypic characteristics compared to social affect [56]. Furthermore, most therapeutic interventions target primarily communication and social skills development while addressing restricted and repetitive behaviours to a lesser degree [57].

Children receiving specific intervention had an improvement in their ADOS total scores over time, consistent with previous meta-analyses of the positive effects of early specific intervention for children with autism spectrum disorder [58]. However, the studies investigating specific interventions using CSS as outcome measure did not show such improvement, which again could indicate an artificial effect due to module changes. The sub-analysis of specific interventions with ADOS total scores as the outcome measure included only four studies (234
participants) of which none were RCTs [17,21,24,36] and only one was of good quality [36]. Furthermore, we could not confirm a significant impact of carer training on reducing autism severity, contrary to the results in a previous systematic review on parent-mediated early intervention for young children [59], possibly due to the limited number of studies targeting parent/carer in our meta-analysis (4 RCTs, 97 participants). These results therefore need to be interpreted with caution. The sub-analysis of type of participants revealed that participants at risk of autism spectrum disorder (mostly sibling studies) showed deterioration in overall severity of autism symptoms as expressed in CSS compared to individuals already diagnosed with autism spectrum disorder. This might be due to the significant number of autism spectrum disorder siblings that progress to full-blown autism spectrum disorder in the course of the first three years of life [60]. The final set of sub-analysis showed that duration of follow-up plays a significant role in predictors of severity of social affect and restricted and repetitive behaviour. Symptoms tended to improve more with increasing follow-up duration, however the findings are limited by the fact that only one study (with two samples) had a follow-up of more than seven years [11]. The improvement was small, with predicted ten-year change in social affect and restricted and repetitive behaviour being less than one point. The sub-analysis of participants’ age indicated that participant age at baseline did not come out as a moderating factor of outcome at follow-up, consistent with autism being a neurodevelopmental disorder and fairly stable in its expression.

Limitations

This review was limited by the quality of reporting in the studies included. Results reported in different formats (raw scores, CSS, subscales, total scores) and without indication of ADOS version posed a major challenge in extracting data and impacted the meta-analyses. We contacted authors to request missing data or clarification, and successfully obtained requested data in some cases.

The limited number of high quality studies both for intervention and follow-up further limit the strength of the evidence. Most commonly, studies only reported on children that were included at both baseline and follow-up, while failing to detail the total number of children available at baseline. Attrition may introduce bias of uncertain direction as parents of children with either a very good outcome or very poor outcome may be less likely to engage in a follow-up study. Moreover, blinding is difficult to achieve and remains a factor in determining the accuracy of results for intervention studies.

It may also be that some studies reported on overlapping samples. Unfortunately, it was not possible from the papers to identify such overlap unambiguously. However, even if samples actually overlapped, they were not included in the same meta-analyses as long as the studies reported different ADOS measures. Therefore, while overlapping samples may have distorted descriptive statistics such as the total number of participants included in the review, they seem unlikely to have led to incorrect estimates in meta-analyses.

The included studies had high levels of clinical heterogeneity precluding firm conclusions, with variations in the type of the ADOS applied (ADOS/ADOS-G/ADOS-2/ADOS toddler version) and different versions available in different countries. More research is needed to systematically explore such variations and learn from such comparisons. Further analysing the various clinical subdivisions made in several studies (Table 1) would be relevant, but was out of scope of this review and would require individual participant data, which from most studies were not available.

While some studies included information about the participants’ cognitive skills, many did not. Therefore, it was not possible to explore cognitive development as a predictor of outcome.

The evidence is limited to the childhood period as there were no studies of adults or following children into adulthood in our review. One study [60] that followed the diagnostic stability...
of Asperger Syndrome did find that a minority (22%) of children did not fulfill the criteria in adulthood. However, that study did not use the ADOS to evaluate changes and therefore did not meet our stringent criteria.

Implications for research and practice

The temporal stability of autism spectrum disorder/autism diagnosis and core symptom severity as measured by the ADOS puts solid evidence behind the definition of autism spectrum disorder as a neurodevelopmental condition/trait similar to intellectual disability, learning disability or social learning disability. While only five studies were RCTs investigating intervention outcomes, all studies included children receiving some form of intervention. Despite this fact, overall outcomes at follow-up did not show any significant change in core autism symptoms. These results indicate a need to redefine the focus of autism spectrum disorder intervention and support. Rather than targeting core autism symptoms, our results suggest that intervention studies should focus on other measures of outcome such as quality of life and adaptive functioning.

There is a great need for rigorously designed studies including larger sample sizes with transparent and complete reporting of study results. Very few intervention studies were randomized and applied blinding of assessment at outcome, creating a high risk of bias. Future studies should aim to publish or make available results both as expressed in ADOS total scores, raw scores and CSS, and they should also specify which ADOS version is being used. Studies wanting to claim treatment gains from intervention should be requested to report CSS to avoid artificial effects of module changes.

The great stability of the ADOS scores and the limited range suggests, as has been indicated previously [56], that the ADOS is not a good measure of change. ASD research is in great need of better autism measures, including also biomarkers and such work is ongoing [61]. In the meantime, intervention studies should strive to examine alternative measures such as quality of life and daily function. Finally, greater efforts are needed to ensure longer follow-up, and studies into adulthood to assess the long-term outcome of an autism spectrum disorder/autism diagnosis.

Conclusions

Our findings indicate a remarkable stability of overall autism severity and autism symptoms over time across childhood on a group level. On a sub-group level, the only robust finding was that children at high risk deteriorated over time (observed in CSS, $I^2 = 23\%$). Using ADOS total scores, 18% of participants shifted from autism to autism spectrum disorder diagnosis, however the overall autism spectrum disorder prevalence was unchanged. The results confirmed that ADOS CSS is one of the most robust (regardless of age, cognitive ability or language) measures of autism severity available, and seems to measure autism symptoms in a similar way as intellectual quotient measure cognitive ability. As evidenced by other studies, individual trajectories do change over time, but at the group level the ADOS CSS are stable across childhood. In addition to confirming the stability of autism spectrum disorder over time, this review highlights a need for improved transparency in research reporting and for rigorously designed studies including larger sample sizes with complete reporting of study results to enable comparisons across studies.

Supporting information

S1 Checklist. PRISMA-P checklist. Lists the reporting of important methodological details in the review protocol.

(DOCX)
S2 Checklist. PRISMA checklist. Lists the reporting of important methodological details in the final review.

S1 Protocol. Protocol for systematic review. Prespecified protocol as used in the review process.

S1 Fig. Overall severity of autism symptoms (Calibrated Severity Scores), split by participant type.

S2 Fig. Proportion meeting autism spectrum disorder criteria (ADOS instrument classification), split by participant type.

S1 Dataset. Data and syntax. Contains data used for meta-analysis and R syntax to reproduce the analyses.

Acknowledgments
The authors would like to acknowledge Dana Yakobson for her contribution in data extraction. Johanna Finnemann and Laura Fusar Poli provided valuable comments on an earlier draft of the manuscript.

Author Contributions
Conceptualization: ŁB, MBP, MG, CG.
Data curation: ŁB, MBP, MG, GT, CE, CG.
Formal analysis: CG, GT.
Funding acquisition: CG.
Investigation: ŁB, MBP, MG, GT, CE, CG.
Methodology: CG.
Project administration: ŁB, GT.
Resources: CG.
Software: CG.
Supervision: CG.
Validation: ŁB, MBP, MG, GT, CG.
Visualization: ŁB, CG.
Writing – original draft: ŁB, MBP, CG.
Writing – review & editing: ŁB, MBP, MG, GT, CE, CG.

References
1. Baxter AJ, Brugha TS, Erskine HE, Scheurer RW, Vos T, Scott JG. The epidemiology and global burden of autism spectrum disorders. Psychol Med. 2015 Feb; 45(3):601–13. doi: 10.1017/S003329171400172X. Epub 2014 Aug 11. PMID: 25108395
1. Buescher AV, Cidav Z, Knapp M, Mandell DS. Costs of autism spectrum disorders in the United Kingdom and the United States. JAMA Pediatr. 2014 Aug; 168(8):721–8. https://doi.org/10.1001/jamapediatrics.2014.210. PMID: 24911948

2. Steinhausen HC, Mohr Jensen C, Lauritsen MB. A systematic review and meta-analysis of the long-term overall outcome of autism spectrum disorders in adolescence and adulthood. Acta Psychiatr Scand. 2016 Jun; 133(6):445–52. doi: 10.1111/acps.12559. Epub 2016 Jan 13. PMID: 26763353

3. McPheeters ML, Weitlauf A, Vehorn A, Taylor C, Sathe NA, Krishnaswami S, et al. Screening for Autism Spectrum Disorder in Young Children: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Evidence Synthesis no 129 AHRQ Publication No. 13-05185-RE-1. Rockville, MD: Agency for Healthcare Research and Quality; 2016.

4. Woolfenden S, Sarkozy V, Ridley G, Williams K. A systematic review of the diagnostic stability of autism spectrum disorder. Res Autism Spectr Disord. 2012 Jan-Mar; 6(1):345–354.

5. Gotham K, Pickles A, Lord C. Standardizing ADOS scores for a measure of severity in autism spectrum disorders. J Autism Dev Disord. 2009 May; 39(5):693–705. doi: 10.1007/s10803-008-0674-3. Epub 2008 Dec 12. PMID: 19082876

6. Lord C, Rutter M, DiLavore PS, Risi, S. Autism Diagnostic Observation Schedule (ADOS). Los Angeles: Western Psychological Services; 2006.

7. Rutter M, Le Couteur A, Lord C. Autism Diagnostic Interview-Revised. Los Angeles: Western Psychological Services; 2003.

8. Risi S, Lord C, Gotham K, Corsello C, Chrysler C, Szatmari P, et al. Combining information from multiple sources in the diagnosis of autism spectrum disorders. J Am Acad Child Adolesc Psychiatry. 2006 Sep; 45(9):1094–103. https://doi.org/10.1097/01.chi.0000227880.42780.ee PMID: 16926617

9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). 5th Edition. Arlington, VA: American Psychiatric Publishing, 2013.

10. Anderson DK, Liang JW, Lord C. Predicting young adult outcome among more and less cognitively able individuals with autism spectrum disorders. J Child Psychol Psychiatry. 2014 May; 55(5):485–94. doi: 10.1111/jcpp.12178. Epub 2013 Dec 9. PMID: 24313878

11. Kleinman JM, Ventola PE, Pandey J, Verbalis AD, Barton M, Hodgson S, et al. Diagnostic stability in very young children with autism spectrum disorders. J Autism Dev Disord. 2008; 38(4):606–615. https://doi.org/10.1007/s10803-007-0042-7 PMID: 17924183

12. Landa RJ, Gross AL, Stuart EA, Faherty A. Developmental trajectories in children with and without autism spectrum disorders: the first 3 years. Child Dev. 2013 Mar-Apr; 84(2):429–42. doi: 10.1111/j.1467-8624.2012.01870.x. Epub 2012 Oct 30. PMID: 2310514

13. Lord C, Risi S, DiLavore PS, Shulman C, Thurm A, Pickles A. Autism from 2 to 9 years of age. Arch Gen Psychiatry. 2006; 63(3):694–701.

14. Messinger DS, Young GS, Webb SJ, Ozonoff S, Bryson SE, Carter A, et al. Early sex differences are not autism-specific: A Baby Siblings Research Consortium (BSRC) study. Mol Autism. 2015 Jun 4; 6:32. doi: 10.1186/s13229-015-0027-y. eCollection 2015. PMID: 26045943

15. van Daalen E, Kemner C, Dietz C, Swinkles SHN, Buitelaar JK, van Engeland H. Inter-rater reliability and stability of diagnoses of autism spectrum disorder in children identified through screening at a very young age. Eur Child Adolesc Psychiatry. 2009 Nov; 18(11):663–74. doi: 10.1007/s00787-009-0025-8. Epub 2009 May 7. PMID: 19421728

16. Ben Itzchak E, Zachor DA. Change in autism classification with early intervention: Predictors and outcomes. Res Autism Spectr Disord. 2009 Oct-Dec; 3(4):967–976.

17. Chawarska K, Klin A, Paul R, Macari S, Volkmar F. A prospective study of toddlers with ASD: short-term diagnostic and cognitive outcomes. J Child Psychol Psychiatry. 2009 Oct; 50(10):1235–45. doi: 10.1111/j.1469-7610.2009.02101.x. Epub 2009 Jul 6. PMID: 19594835

18. Chawarska K, Scic F, Macari S, Campbell DJ, Brian J, Landa R, et al. 18-month predictors of later outcomes in younger siblings of children with autism spectrum disorder: a baby siblings research consortium study. J Am Acad Child Adolesc Psychiatry. 2014 Dec; 53(12):1317–1327.e1. doi: 10.1016/j.jaac.2014.09.015. Epub 2014 Oct 2. PMID: 25457930

19. Ozonoff S, Young GS, Belding A, Hill M, Hill A, Hutman T, et al. The broader autism phenotype in infancy: when does it emerge? J Am Acad Child Adolesc Psychiatry. 2014 Apr; 53(4):398–407.e2. doi: 10.1016/j.jaac.2013.12.020. Epub 2014 Jan 21. PMID: 24655649

20. Di Renzo M, Bianchi Di Castelbianco F, Petrillo M, Racinaro L, Rea M. Assessment of a long-term developmental relationship-based approach in children with autism spectrum disorder. Psychol Rep. 2015 Aug; 117(1):26–49. doi: 10.2466/15.10.PR.117c1528. Epub 2015 Aug 13. PMID: 26270989

21. Gammer I, Bedford R, Elsabbagh M, Garwood H, Pasco G, Tucker L, et al. Behavioural markers for autism in infancy: scores on the Autism Observational Scale for Infants in a prospective study of at-risk
siblings. Infant Behav Dev. 2015 Feb; 38:107–15. doi: 10.1016/j.infbeh.2014.12.017. Epub 2015 Feb 2. PMID: 25656952

23. Akshoomoff N, Lord C, Lincoln AJ, Courchesne RY, Carper RA, Townsend J, Courchesne J. Outcome classification of preschool children with autism spectrum disorders using MRI brain measures. J Am Acad Child Adolesc Psychiatry. 2004 Mar; 43(3):349–57. https://doi.org/10.1097/00004583-200403000-00018 PMID: 15076269

24. Lerna A, Esposito D, Conson M, Massaglia M. Long-term effects of PECS on social-communicative skills of children with autism spectrum disorders: a follow-up study. Int J Lang Commun Disord. 2014 Jul-Aug; 49(4):478–85. doi: 10.1111/1460-6984.12079. Epub 2014 Mar 21. PMID: 24655345

25. Aldred C, Green J, Adams C. A new social communication intervention for children with autism: pilot randomised controlled treatment study suggesting effectiveness. J Child Psychol Psychiatry. 2004 Nov; 45(8):1420–30. https://doi.org/10.1111/j.1469-7610.2004.00848.x PMID: 15482502

26. Brian J, Bryson SE, Garon N, Roberts W, Smith IM, Szatmari P, Zwaigenbaum L. Clinical assessment of autism in high-risk 18-month-olds. Autism. 2008 Sep; 12(5):433–56. https://doi.org/10.1177/1362361308094500 PMID: 18805941

27. Dawson G, Rogers S, Munson J, Smith M, Winter J, Greenenson J, et al. Randomized, controlled trial of an intervention for toddlers with autism: The Early Start Denver Model. Pediatrics. 2010 Jan; 125(1): e17–23. doi: 10.1542/peds.2009-0958. Epub 2009 Nov 30. PMID: 19948568

28. Dereu M, Roeyers H, Raymaekers R, Meirsschaut M, Warreyn P. How useful are screening instruments for toddlers to predict outcome at age 4? General development, language skills, and symptom severity in children with a false positive screen for autism spectrum disorder. Eur Child Adolesc Psychiatry. 2012 Oct; 21(10):541–51. doi: 10.1007/s00787-012-0280-y. Epub 2012 May 13. PMID: 22580987

29. Freitag CM, Feineis-Matthews S, Valerian J, Teufel K, Wilker C. The Frankfurt early intervention program FFIP for preschool aged children with autism spectrum disorder: A pilot study. J Neural Transm (Vienna). 2012 Sep; 119(9):1011–21. doi: 10.1007/s00702-012-0792-0. Epub 2012 Mar 30. PMID: 22460295

30. Gotham K, Pickles A, Lord C. Trajectories of autism severity in children using standardized ADOS scores. Pediatrics. 2012 Nov; 130(5):e1278–84. doi: 10.1542/peds.2011-3668. Epub 2012 Oct 22. PMID: 23090336

31. Green J, Charmian T, McConachie H, Aldred C, Slonims V, Howlin P, et al. Parent-mediated communication-focused treatment in children with autism (PACT): A randomised controlled trial. Lancet. 2010 Jun 19; 375(9732):2152–60. doi: 10.1016/S0140-6736(10)60587-9. Epub 2010 May 20. PMID: 20494434

32. Guthrie W, Swineford LB, Nottke C, Wetherby AM. Early diagnosis of autism spectrum disorder: Stability and change in clinical diagnosis and symptom presentation. J Child Psychol Psychiatry. 2013 May; 54(5):582–90. https://doi.org/10.1111/jcpp.12038 PMID: 23078094

33. Gutstein SE, Burgess AF, Montfort K. Evaluation of the relationship development intervention program. Autism. 2007 Sep; 11(5):397–411. https://doi.org/10.1177/1362361307098603 PMID: 17942454

34. Hobson JA, Tarver L, Beurkens N, Hobson RP. The relation between severity of autism and caregiver-child interaction: A study in the context of relationship development intervention. J Abnorm Child Psychol. 2016 May; 44(4):745–55. https://doi.org/10.1007/s10802-015-0067-y PMID: 26298470

35. Howlin P, Gordon RK, Pasco G, Wade A, Charmian T. The effectiveness of Picture Exchange Communication System (PECS) training for teachers of children with autism: A pragmatic, group randomised controlled trial. J Child Psychol Psychiatry. 2007 May; 48(5):473–81. https://doi.org/10.1111/j.1469-7610.2006.01707.x PMID: 17501728

36. Klintwall L, Macari S, Eikeseth S, Chawarska K. Interest level in 2-year-olds with autism spectrum disorder predicts rate of verbal, nonverbal, and adaptive skill acquisition. Autism. 2015 Nov; 19(8):925–33. doi: 10.1177/1362361314555376. Epub 2014 Nov 14. PMID: 25398893

37. Lord C, Luytser R. Early diagnosis of children with autism spectrum disorders. Clin Neurosci Res. 2006 Oct; 6(3–4):189–194. https://doi.org/10.1016/j.cnr.2006.06.006

38. Lord C, Luytser R, Guthrie W, Pickles A. Patterns of developmental trajectories in toddlers with autism spectrum disorder. J Consult Clin Psychol. 2012 Jun; 80(3):477–89. doi: 10.1037/a0027214. Epub 2012 Apr 16. PMID: 22506796

39. Louwerse A, Eussen ML, Van der Ende J, de Nijs PF, Van Gool AR, Dekker LP, et al. ASD symptom severity in adolescence of individuals diagnosed with PDD-NOS in childhood: Stability and the relation with psychiatric comorbidity and societal participation. J Autism Dev Disord. 2015 Dec; 45(12):3906–18. https://doi.org/10.1007/s10803-015-2595-2 PMID: 26395112

40. Macari SL, Campbell D, Gengoux GW, Saulnier CA, Klin AJ, Chawarska K. Predicting developmental status from 12 to 24 months in infants at risk for Autism Spectrum Disorder: a preliminary report. J
41. Mosconi MW, Steven Reznick J, Mesibov G, Piven J. The Social Orienting Continuum and Response Scale (SOC-RS): A dimensional measure for preschool-aged children. J Autism Dev Disord. 2009 Feb; 39(2):242–50. doi: 10.1007/s10803-008-0620-4. Epub 2008 Jul 22. PMID: 18648919

42. Ray-Subramanian CE, Weismer SE. Receptive and expressive language as predictors of restricted and repetitive behaviors in young children with autism spectrum disorders. J Autism Dev Disord. 2012 Oct; 42(10):2113–20. https://doi.org/10.1007/s10803-012-1463-6 PMID: 22350337

43. Richler J, Huerta M, Bishop SL, Lord C. Developmental trajectories of restricted and repetitive behaviors and interests in children with autism spectrum disorders. Dev Psychopathol. 2010 Winter; 22(1):55–69. https://doi.org/10.1017/S0954579409990265 PMID: 21026477

44. Shumway S, Farmer C, Thurman A, Joseph L, Black D, Golden C. TheADOS calibrated severity score: Relationship to phenotypic variables and stability over time. Autism Res. 2012 Aug; 5(4):267–76. doi: 10.1002/aur.1238. Epub 2012 May 24. PMID: 22628087

45. Solomon R, Van Egeren LA, Mahoney G, Quon Huber MS, Zimmerman P. PLAY Project Home Consultation intervention program for young children with autism spectrum disorders: A randomized controlled trial. J Dev Behav Pediatr. 2014 Oct; 35(8):475–85. https://doi.org/10.1097/DBP.0000000000000961 PMID: 25264862

46. Szatmari P, Chawarska K, Dawson G, Geogrides S, Landa R, Lord C, Messinger DS, Thurman A, Halladay A. Prospective Longitudinal Studies of Infant Siblings of Children With Autism: Lessons Learned and Future Directions. J Am Acad Child Adolesc Psychiatry. 2016 Mar; 55(3):179–87. doi: 10.1016/j.jaac.2015.12.014. Epub 2016 Jan 8. PMID: 26903251

47. Thurman A, Manwaring SS, Swineford L, Farmer C. Longitudinal study of symptom severity and language in minimally verbal children with autism. J Child Psychol Psychiatry. 2015 Jan; 56(1):97–104. doi: 10.1111/jcpp.12285. Epub 2014 Jun 24. PMID: 24961159

48. Turner LM, Stone WL. Variability in outcome for children with an ASD diagnosis at age 2. J Child Psychol Psychiatry. 2007 Aug; 48(8):793–802. https://doi.org/10.1111/j.1469-7610.2007.01744.x PMID: 17683451

49. Venker CE, Ray-Subramanian CE, Bolt DM, Ellis Weismer S. Trajectories of autism severity in early childhood. J Autism Dev Disord. 2014 Mar; 44(3):546–63. https://doi.org/10.1007/s10803-013-1903-y PMID: 23907710

50. Vivanti G, Paynter J, Duncan E, Fothergill H, Dissanayake C, Rogers SJ, Victorian ASELCC Team (2014). Effectiveness and feasibility of the Early Start Denver Model implemented in a group-based community childcare setting. J Autism Dev Disord. 2014 Dec; 44(12):3140–53. https://doi.org/10.1007/s10803-014-2168-9 PMID: 24974255

51. Zachor DA, Ben-Itzhak E, Rabinovich AL, Lahat E. Change in autism core symptoms with intervention. Res Autism Spectr Disord 2007 Oct-Dec; 1(4):304–317.

52. Matson JL, Horovitz M. Stability of autism spectrum disorders symptoms over time. J Dev Phys Disabil. 2010 Aug; 22(4):331–42. https://doi.org/10.1007/s10882-010-9188-7

53. Rondeau E, Klein LS, Masse A, Bodeau N, Cohen D, Guille JM. Is pervasive developmental disorder not otherwise specified less stable than autistic disorder? A meta-analysis. J Autism Dev Disord. 2011 Sep; 41(9):1267–76. https://doi.org/10.1007/s10803-010-1155-z PMID: 21153874

54. de Bildt A, Oosterling I, van Lang N, Sytema S, Minderaa R, van Engeland H, et al. Standardized ADOS scores: Measuring severity of autism spectrum disorders in a Dutch sample. J Autism Dev Disord. 2011 Mar; 41(3):311–9. https://doi.org/10.1007/s10803-010-1057-0 PMID: 20617374

55. Hus V, Gotham K, Lord K. Standardizing ADOS domain scores: separating severity of social affect and restricted and repetitive behaviors. J Autism Dev Disord. 2014 Oct; 44(10):2400–12. https://doi.org/10.1007/s10803-014-1719-1 PMID: 23143131

56. Boyd BA, McDonough SG, Bodfish JW. Evidence-based behavioral interventions for repetitive behaviors in autism. J Autism Dev Disord. 2012 Jun; 42(6):1236–48. https://doi.org/10.1007/s10803-011-1284-2 PMID: 21584849

57. Reichow B. Overview of meta-analyses on early intensive behavioral intervention for young children with autism spectrum disorders. J Autism Dev Disord. 2012 Apr; 42(4):512–20. https://doi.org/10.1007/s10803-011-1218-9 PMID: 21404863

58. Oono IP, Honey EJ, McCauley H. Parent-mediated early intervention for young children with autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2013 Apr 30;(4):CD009774. https://doi.org/10.1002/14651858.CD009774.pub2 PMID: 23633377

59. Szatmari P, Geogrides S, Duku E, Bennett TA, Bryson S, Fombonne E, et al. Developmental trajectories of symptom severity and adaptive functioning in an inception cohort of preschool children with...
autism spectrum disorder. JAMA Psychiatry. 2015 Mar; 72(3):276–83. https://doi.org/10.1001/jamapsychiatry.2014.2463 PMID: 25629657

60. Helles A, Gillberg CI, Gilberg C, Billstedt E. Asperger syndrome in males over two decades: stability and predictors of diagnosis. J Child Psychol Psychiatry. 2015 Jun; 56(6):711–8. https://doi.org/10.1111/jcpp.12334 PMID: 25283685

61. Loth E, Spooren W, Ham LM, Isaac MB, Auriche-Benichou C, Banaschewski T, et al. Identification and validation of biomarkers for autism spectrum disorders. Nat Rev Drug Discov. 2016 Jan; 15(1):70–3. https://doi.org/10.1038/nrd.2015.7 PMID: 26718285